November 30, 2017
US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings.
EXTON, Pa., Nov. 30, 2017 /PRNewswire/ — The most recent release of RealTime Dynamix™: Atopic Dermatitis reveals steady uptake of the newest atopic dermatitis launches, Dupixent and Eucrisa. Both agents have consistently enjoyed substantial user- and patient-base gains quarter over quarter since launching, with the vast majority of collaborating dermatologists reporting current clinical experience. Furthermore, projected use is also favorable for both brands.
Despite widespread use and continued positive projections, dermatologists’ perceptions of Eucrisa are not so rosy. Eucrisa garners the lowest satisfaction ratings among all approved atopic dermatitis treatments, with only one in ten citing that they are very satisfied with the topical PDE4 inhibitor. Additionally, as familiarity with the brand has significantly increased over the year, the percentage of dermatologists who view Eucrisa as an advance over other topicals has significantly declined. However, the majority of respondents have had at least some exposure to a Pfizer representative for Eucrisa and generally speaking, the representatives are rated as performing very well in all areas. Furthermore, Eucrisa’s direct to consumer (DTC) campaign is generally well-received among dermatologists and roughly one-third of respondents note that they have seen an increase in patient requests for Eucrisa since the launch of Pfizer’s DTC campaign—an important factor given that nearly two-thirds of patient inquiries for the brand resulted in a Eucrisa prescription.
On the other end of the spectrum, dermatologists are significantly more satisfied with Dupixent, the only approved biologic for atopic dermatitis, than they are with more traditional pharmacologic treatments such as topical steroids, topical calcineurin inhibitors, immunomodulators, or Eucrisa. Familiarity among dermatologists is significantly on the rise and is a decreasing barrier for use of the biologic. Consistent with prior quarters, the vast majority of respondents continue to view Dupixent as a significant advance over other treatment options for atopic dermatitis, and the majority also report that they are extremely comfortable with Dupixent as a treatment for their adult atopic dermatitis patients. Though nearly one out of five respondents have yet to see a Dupixent sales representative, those who have rate the representative as performing very well across all metrics, but especially with regard to their knowledge of Dupixent. Barriers for adoption and increased use of the brand come in the form of the common insurance and out of pocket cost hurdles, issues that are unlikely to dissipate anytime in the near future.
Though the atopic dermatitis pipeline is bursting with development, Dupixent is likely to maintain it’s first and only biologic on the atopic dermatitis market status for quite some time, and the majority of dermatologists agree that Dupixent’s status as the first ever approved biologic for AD will be a substantial advantage over subsequent biologic approvals.
In general, dermatologists are not highly familiar with specific compounds in development, though oral small molecules that come with biologic-style efficacy are highly desired. Despite the lack of familiarity, the majority of dermatologists report having learned more about all of the leading agents in development within the past three months. Dermatologists’ preferred choice for FDA approval is AbbVie’s JAK, upadacitinib, followed by Eli Lilly’s baricitinib (Olumiant), Galderma’s nemolizumab, and LEO’s tralokinumab. At this juncture, the relationship with the manufacturer, particularly for upadacitinib and AbbVie, is a key driver behind interest in and preference for pipeline agents.
RealTime Dynamix™: Atopic Dermatitis is an independent report series published on a quarterly basis. The series tracks the evolution of the atopic dermatitis market, provides a deep dive on launch effectiveness, and highlights opportunities for pipeline agents.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and market research agency, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document are trademarks of their respective holders.
To view media coverage of this release, click here.